Natixis Advisors, L.P. Genmab A/S Call Options Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GMAB
# of Institutions
238Shares Held
52.6MCall Options Held
10.2KPut Options Held
25.5K-
Alliancebernstein L.P. New York, NY15.1MShares$307 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$103 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA4.42MShares$89.8 Million0.02% of portfolio
-
Harding Loevner LP Bridgewater, NJ3.07MShares$62.3 Million0.44% of portfolio
-
Wellington Management Group LLP Boston, MA2.31MShares$46.8 Million0.01% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $13.4B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...